Introduction: Severe hypoglycemia is a burden for both patients and the healthcare system
INTRODUCTION
Hypoglycemia is a common and serious side effect associated with glucose-lowering therapies. Hypoglycemia occurs frequently in insulin-treated patients, and prevalence is higher in patients with type 1 diabetes (T1D) than type 2 diabetes (T2D), but increases in frequency in T2D with disease duration as treatment intensifies [1] [2] [3] . Hypoglycemia is a major burden for the healthcare sector and society, due to the treatment cost and the associated lost productivity [4] [5] [6] ; it is also a burden for patients, resulting in fear and anxiety, and disruption to their sleep, and their domestic and social life [4, 7, 8] . Moreover, hypoglycemia is associated with death, adverse cardiovascular outcomes, dementia, falls, and fractures [9] . Furthermore, hypoglycemia can occur suddenly and with varying severity [4, 9] . Severe hypoglycemic events (SHEs, requiring third-party assistance) may require hospitalization and inpatient care, leading to significant resource use and costs [10] [11] [12] .
The aim of this study was to quantify the resource use and expense associated with an SHE in adult patients with diabetes, using the Maccabi Healthcare Services (MHS) database registry. The majority of studies investigating resource use following hypoglycemia provide retrospective data on resource use after an event, with many only including patients who report resource use. This study is unique in that data were collected before and after an SHE for a designated time period, enabling assessment of the change in resource use after an SHE. The time period under consideration for this analysis was 1 month pre-SHE and 1 month post-SHE.
METHODS

MHS is the second-largest Health Management
Organization (HMO) 
RESULTS
Study Population
A total of 3975 patients were eligible for inclusion in the study; their characteristics at index/time of SHE are summarized in Table 1 . Overall, 7.1% of patients in the study were categorized as T1D (n = 284), and 92.9% as T2D (n = 3691 During 9 years of the study, there were only slight and insignificant differences in the number of SHEs reported by patients with diabetes in the registry each year.
Hospital Visits
In the month following an SHE, 25% (n = 992) of the study population were hospitalized and 10% (n = 401) visited the emergency Data are mean ± standard deviation, unless otherwise specified BMI body mass index, SHE severe hypoglycemic event, T1D type 1 diabetes, T2D type 2 diabetes a On a scale from 1 (lowest) to 20 (highest)
department. The number of hospital admissions increased significantly (by 95% for T1D and by 127% for T2D, P\0.001) in the month following the SHE (Table 2 ) compared with the month before the SHE. Additionally, the proportion of patients with 1, 2, or 3?
hospital admissions also increased significantly during this period versus the previous month (Fig. 1) . The proportion of patients with T1D hospitalized on one occasion increased 1 month post-SHE but there was no increase in the number of patients requiring two or three hospitalizations. In patients with T2D, there was an increase in the proportion of patients with 1, 2, and 3? hospitalizations 1 month post-versus 1 month pre-SHE.
Of the patients admitted to hospital preand/or post-SHE (T1D: n = 59, 1.4%; T2D: n = 1214, 30.5%), the overall mean duration of stay was significantly longer during the month post-versus pre-SHE in both patients with T1D and T2D (T1D: 2.08 vs. 0.88 days, P = 0.036; T2D: 4.17 vs. 1.45 days, P\0.001; Table 3 ). The mean increase in hospital stay post-SHE was longer in patients with T1D and T2D admitted for non-surgical procedures and patients with T2D admitted for surgical procedures, but not patients with T1D admitted for surgical procedures (Table 3) . Of the 1273 patients who were hospitalized in the month pre-or post-SHE, 148 (3.7% of the total study population; 11.6% of the hospitalized patients) were hospitalized both in the month pre-and the month post-SHE. The mean duration of stay in patients with T2D hospitalized pre-and post-SHE was significantly longer in the month post-SHE compared with the month pre-SHE (9.36 vs. 5.84 days, P = 0.002), whereas there was no significant difference in those with T1D (Table 3 ).
In the month following an SHE, the total number of outpatient visits increased significantly from 744 to 1022 (37% increase, P\0.001) in patients with T1D, and from 10,626 to 15,685 (47% increase, P\0.001) in patients with T2D. The greatest increases were in visits to endocrinologists, nurses, and dieticians (Table 4 ). There was a non-significant increase in outpatient pathology, radiology, and imaging visits, and a significant increase in the number of (Table 4) . There was also a significant increase in the number of medication purchases post-SHE, including a 61% increase in SMBG sticks purchases in patients with T2D (P\0.001) and a 20% increase in diabetic medication purchases in patients with T1D (P = 0.014; Table 4 ).
Cost of Treatment
The increase in frequency and duration of hospitalization and the frequency of outpatient visits resulted in a significant increase in the total costs, hospital costs, and outpatient costs in the month following an SHE compared with the month before (Fig. 2) . The total expense per patient per month increased by 46% (P = 0.001) from $485 to $708 for T1D
and 87% (P\0.001) from $601 pre-SHE to $1121 post-SHE for T2D. The greatest expense, and the greatest increase in expense, was hospitalization, with an increase per patient per month from $112 to $312 (?179%, P = 0.003) in T1D, and from $265 to $706 (?166%, P\0.001) in T2D. Additionally, there was a significant increased expenditure of 37% in T1D and 46% in T2D for visits to healthcare specialists, and 34% in T2D for emergency department visits in the month following an SHE compared with the month pre-SHE (Fig. 2) .
In this analysis, there was no significant change in the expenses associated with pathology, radiology, and imaging or lab tests.
As additional sensitivity analyses, healthcare expenses were also stratified by BMI, socioeconomic index, whether or not the patient was insulin treated, Charlson comorbidity index, and HbA 1c (Table 5 ). There were no significant differences in expenses across BMI categories, socioeconomic status, (Table 5) .
DISCUSSION
In this real-world, non-interventional analysis of data from a large-scale diabetes registry, severe hypoglycemia was associated with While it is recognized that factors other than the SHE could influence the data over the time period, the non-significant change in pathology, radiology, and imaging visits would suggest that there was no change in concomitant serious illnesses.
The increase in the proportion of patients with 1, 2, and 3? hospitalizations and the increase in length of hospital stay 1 month post-versus 1 month pre-SHE were higher for patients with T2D compared with T1D, possibly due to the higher rate of comorbidities and greater age in these populations. It is possible that patients with T1D and their carers may also have more experience at coping with SHEs, and therefore be less inclined to go to the hospital, compared with patients with T2D who may not be insulin treated or have been treated with insulin for a shorter duration, and therefore have experienced fewer SHEs. It should also be noted that the number of patients in the T1D category was smaller than in the T2D category, and this may partly explain why the results did not reach significance. However, other studies have also shown that hospitalization for severe hypoglycemia is more frequent in patients with T2D compared with T1D [10, 17] . These include a study of the resource use associated with severe hypoglycemia in insulin-treated patients with diabetes from a large clinical trial program, which showed that severe hypoglycemia often results in the use of emergency services or ambulance calls and in hospital treatment [17] .
Severe hypoglycemia is recognized as a common cause of hospitalization in elderly patients with diabetes and those with comorbidities [18, 19] , and in one study accounted for 94.6% of all endocrine emergency hospitalizations in older patients [20] .
The results presented here are consistent with those from several other studies reporting the extensive resource use and cost implications of severe hypoglycemia for healthcare providers/payers. Although the costs vary depending on the countries included and their healthcare systems [6, 10-12, 17, 21] , together they illustrate that hypoglycemia is a significant burden and that efforts to minimize it are likely to reduce the economic burden of diabetes.
Previous studies into hypoglycemia-related resource use did not compare the before and after costs for a specific population of patients.
This study benefits from the pre-and post-event design, allowing for elucidation of the change in resource use and expenses to be compared, while correcting for background resource use. In support of the robustness of these results, sensitivity analyses conducted with 1 week and 1 year pre-and post-SHE data showed similar results (data not shown). The study also benefits from the level of detail captured and the size of the population included in the registry.
Following the 1994 Israel National Health Act, MHS may not deny coverage to applicants on any grounds, including age or state of health, and thus these results are a representation of all sectors of the Israeli population, except for young adults aged 18-21 years, due to the Some patients were hospitalized pre-SHE;
however, in the patients who were hospitalized both pre-and post-SHE, the duration of stay was significantly increased post-SHE, so experiencing an SHE may have contributed to their longer hospital stay. The number of patients with T1D included in the analysis was low, and they may not be considered a representative sample of patients with T1D because of their age ([18 years) and late diagnosis age (around the age of 20 years). It is also not known how many non-severe hypoglycemia events the study population experienced during the designated time period, or whether they contributed to the increase in resource use observed here; nonetheless, this should not affect the conclusion of the study. Furthermore, the patients' diabetes-related complications may also have contributed to resource use. 
ACKNOWLEDGMENTS
This study and the associated article processing charges for publication were funded by Novo Compliance with Ethics Guidelines. All procedures followed were in accordance with 
